Research Analysts Set Expectations for VTYX FY2029 Earnings

Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) - Analysts at HC Wainwright issued their FY2029 EPS estimates for Ventyx Biosciences in a research note issued to investors on Tuesday, January 14th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($1.34) for the year. HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Ventyx Biosciences' current full-year earnings is ($2.09) per share.

Separately, Oppenheimer reaffirmed an "outperform" rating and set a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

Ventyx Biosciences Trading Down 3.3 %

VTYX traded down $0.07 during trading on Thursday, hitting $1.90. 1,024,893 shares of the company's stock traded hands, compared to its average volume of 1,962,213. Ventyx Biosciences has a 12-month low of $1.67 and a 12-month high of $11.48. The company's 50 day simple moving average is $2.28 and its two-hundred day simple moving average is $2.28. The stock has a market capitalization of $134.00 million, a price-to-earnings ratio of -0.80 and a beta of 0.55.

Insider Activity

In other Ventyx Biosciences news, Director Sheila Gujrathi bought 130,000 shares of the business's stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average cost of $2.31 per share, for a total transaction of $300,300.00. Following the completion of the transaction, the director now owns 130,000 shares of the company's stock, valued at $300,300. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John Nuss sold 21,119 shares of the stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $2.36, for a total transaction of $49,840.84. Following the completion of the transaction, the insider now owns 464,582 shares in the company, valued at $1,096,413.52. The trade was a 4.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have bought 630,000 shares of company stock valued at $1,262,415 in the last ninety days. 18.18% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ventyx Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of VTYX. Acadian Asset Management LLC purchased a new position in Ventyx Biosciences during the second quarter valued at $608,000. Vestal Point Capital LP lifted its position in shares of Ventyx Biosciences by 31.2% during the 3rd quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock valued at $3,760,000 after buying an additional 410,000 shares in the last quarter. Barclays PLC lifted its position in shares of Ventyx Biosciences by 273.1% during the 3rd quarter. Barclays PLC now owns 80,295 shares of the company's stock valued at $175,000 after buying an additional 58,776 shares in the last quarter. Deerfield Management Company L.P. Series C increased its holdings in Ventyx Biosciences by 64.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company's stock worth $13,466,000 after acquiring an additional 2,287,570 shares in the last quarter. Finally, Sio Capital Management LLC raised its stake in Ventyx Biosciences by 153.2% during the 3rd quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company's stock worth $4,299,000 after acquiring an additional 1,193,024 shares during the period. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.